Psoriasis: Which therapy for which patient, updated, part I. Focus on Psoriasis Comorbidities and Preferred Systemic Agents. (PubMed, J Am Acad Dermatol) - Oct 20, 2026 - "Selection of the appropriate treatment modality has evolved substantially with the rapid expansion of available options that can be individualized based on patients' comorbidity profiles, extent of disease, prior therapeutic response, and treatment preferences. This first article of a two-part series focuses on selecting systemic therapy for PsO patients with specific inflammatory comorbidities or a history of malignancy."
Journal • Review • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Dermatology • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Heart Failure • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Lupus • Multiple Sclerosis • Nephrology • Oncology • Psoriasis • Psoriatic Arthritis • Renal Disease • Rheumatology • Seronegative Spondyloarthropathies
|
|
Anusha Pasumarthi; Kateryna Karpoff; Mark Lebwohl
|